Pfizer's VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate Pharmaceutical Investing
FDA APPROVES OTEZLA® FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL Market News
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply Pharmaceutical Investing
Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada Psychedelics Investing
Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing Facility Life Science Investing
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States Pharmaceutical Investing
Leveljump Healthcare Corp. Acquires Additional 2.3% of Real Time Medical; Exercises Right to Acquire Additional 1.5% of Shaw Lens and Shaw Vision; Provides Corporate Update Medical Device Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
